European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials	47
Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients	46
Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients	43
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY	41
Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial	40
Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)	39
Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials	35
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle	34
Renal protection in chronic heart failure: focus on sacubitril/valsartan	32
Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis	31
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events	30
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	29
Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial	29
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis	28
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	28
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)	26
Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence	26
Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation	26
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines	25
What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions	25
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	23
The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer	23
Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?	23
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis	22
Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study	22

SGLT2 inhibitors in cardiovascular medicine	21
FLOW trial stopped early due to evidence of renal protection with semaglutide	21
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI	20
Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study	19
Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis	19
Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials	19
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis	19
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consens	18
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials	17
Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes	16
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk	16
Advances in the understanding of excitation-contraction coupling: the pulsing quest for drugs against heart failure and arrhythmias	16
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial	15
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19	15
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus	15
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	14
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19	14
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial	14
Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent	14
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model	14
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry	13
Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway	13
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study	13
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	13
Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry	13
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	12
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking	12
Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management	12
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis	12
Direct oral anticoagulants vs. vitamin K antagonists for the treatment of left ventricular thrombosis: a systematic review of the literature and meta-analysis	12
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and netwo	12
LDL lowering effect of PCSK9 inhibition is reduced in women	12
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis	12
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care	12
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial	12
Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis	12
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	11
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial	11
A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?	11
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on	11
Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)	11
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	11
The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond	10
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials	10
Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH	10
Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design	10
Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?	10
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial	10
Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients	10
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study	10

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial	9
Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis	9
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	9
Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition	9
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries	9
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	9
Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underling possible safety concerns	9
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	9
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation	8
Photoinduced skin reactions of cardiovascular drugs—a systematic review	8
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	8
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?	8
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2	8
Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy	8
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis	7
Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl pepti	7
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study	7
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk	7
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	7
β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction	7
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	7
Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry	7
Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis	7
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48	7
RNA-targeted therapeutics in cardiovascular disease: the time is now	7
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention	7
VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients	6
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease	6
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	6
A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study	6
Cardiovascular risks associated with calcium supplementation in patients with osteoporosis: a nationwide cohort study	6
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	6
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial	6
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases	6
Epinephrine administration for adult out-of-hospital cardiac arrest patients with refractory shockable rhythm: time-dependent propensity score-sequential matching analysis from a nationwide population	6
The neurocognitive effects of atrial fibrillation: benefits of the ABC pathway	6
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD	6
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	6
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy	5
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials	5
Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction	5
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction	5
The association of PRECISE-DAPT score with ischaemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis	5
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	5
Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)	5
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome	5
Are SGLT2 inhibitors effective against ‘all’ heart failure with preserved ejection fraction?	5
Pharmacological and clinical appraisal of factor XI inhibitor drugs	5
Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis	5
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021	5
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial	5
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results	4
The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes	4
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis	4
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	4
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study	4
Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested c	4
The SAMSON trial: using a placebo to improve medication tolerability	4
Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial	4
Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study	4
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies	4
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	4
Fibrates: one more lost paradise in lipid treatment	4
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events	4
The potential future role of extensive lipid lowering in ACS patients with the use of PCSK9 inhibitors: early bird catches the worm	4
Concerns about the use of digoxin in acute coronary syndromes	4
Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study	4
Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study	4
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases	4
Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis	4
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	4
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	3
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation	3
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance	3
Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry	3
Weekend vs. weekday admission and clinical outcomes in heart failure patients with and without atrial fibrillation in Taiwan	3
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide co	3
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study	3
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis	3
Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond	3

Fast vs. ultraslow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial	3
Clopidogrel-associated hypoglycaemia and alternative antiplatelet therapy: a real-world, pharmacovigilance study	3
Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome	3
2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?	3
Vericiguat in the management of heart failure with reduced ejection fraction	3
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinic	3
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	3
New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer tr	3
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry	3
Pharmapulse report—does the arrival of factor XI inhibitors mark the end of the NOAC era?	3
Risk of serious hypoglycaemia in patients with atrial fibrillation and diabetes concurrently taking antidiabetic drugs and oral anticoagulants: a nationwide cohort study	3
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	2
Perioperative management of P2Y12 inhibitors in patients undergoing cardiac surgery within 1 year of PCI	2
Factor XIa inhibitors: collecting the clinical evidence	2
New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021	2
Statin therapy reduces dementia risk in atrial fibrillation patients receiving oral anticoagulants	2
Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry	2
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Reg	2
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity	2
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease	2
Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground	2
Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure	2
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?	2
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics	2
Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial	2
Cardiovascular risks associated with use of non-steroidal anti-inflammatory drugs in patients with non-obstructive coronary artery disease	2
Atrial fibrillation and stroke prevention	2
Commentary regarding the article by Gragnano et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLA	2
Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized study	2
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	2
Comment on Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	2
P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting	2
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	2